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OBJECTIVE: Patients with nasopharyngeal carcinoma experience highly variable outcomes despite receiving
similar therapeutic regimens. Identifying biomarkers that predict survival and guide individualized therapy is
urgently needed. Cystatin C has been explored as a valuable prognostic marker in several malignancies. We
retrospectively assessed the relationship between serum cystatin C levels and nasopharyngeal carcinoma
prognosis in a large cohort of nasopharyngeal carcinoma patients receiving long-term follow-up.
METHODS: A total of 1063 consecutive patients diagnosed with nasopharyngeal carcinoma from June 2006 to
December 2010 were retrospectively analyzed. The serum levels of cystatin C at the time of diagnosis were
collected. Receiver operating characteristic curve analysis, the Kaplan-Meier method and multivariate analyses
using a Cox regression model were performed to assess the correlation of cystatin C levels with overall survival,
progression-free survival, distant metastasis-free survival and loco-regional recurrence-free survival.
RESULTS: The median follow-up duration was 68.3 months. The optimal cut-off value of cystatin C levels for
predicting death was 0.945 mg/L. Compared with the low cystatin C group, the high cystatin C group
experienced significantly shorter overall survival (hazard ratio=1.47, p=0.050), progression-free survival (hazard
ratio=1.65, p=0.004), distant metastasis-free survival (hazard ratio=2.37, po0.001) and loco-regional recurrence-
free survival (hazard ratio=2.40, p=0.002). Based on multivariate analysis, a high cystatin C level was identified
as a significant and independent negative predictor of overall survival (hazard ratio=1.47, p=0.050),
progression-free survival (hazard ratio=1.65, p=0.004), distant metastasis-free survival (hazard ratio=2.37,
po0.001), and loco-regional recurrence-free survival (hazard ratio=2.40, p=0.002).
CONCLUSION: Cystatin C levels are associated with the prognosis of nasopharyngeal carcinoma patients. A high
cystatin C level is an independent indicator of poor prognosis for nasopharyngeal carcinoma patients.
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’ INTRODUCTION
Nasopharyngeal carcinoma is a form of squamous-cell
carcinoma that occurs in the upper epithelial lining of the
nasopharynx (1). Epidemiological studies suggested that NPC
has a remarkable geographic distribution and is especially
prevalent in southern China (2). The annual incidence rate of
NPC reaches approximately 30 per 100,000 in prevalent regions
and this value is 50-fold higher than that in western countries
(3). Although NPC is radio-sensitive, approximately one-third
of NPC patients develop loco-regional recurrence and/or
distant metastasis (4). Therefore, identifying novel markers
for predicting the prognosis of NPC is necessary.
Cystatin C (CysC), an endogenous non-glycosylated
13 kDa inhibitor of cysteine proteases that is constitutively
expressed by all nucleated cells, plays a role in the regulation
of cell proliferation, differentiation and migration (5). It is
encoded by the CST3 gene, which is located on chromosome
20p (6). CysC is cleared via glomerular filtration, reabsorbed
and catabolized by the renal tubules, and is always useful as
an ideal measure of the glomerular filtration rate (GFR). The
serum CysC level is very steady and is only slightly affectedDOI: 10.6061/clinics/2016(06)09
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by age, sex and muscle mass (7). However, the serum CysC
level is elevated in patients with several types of malig-
nances, including lung cancer (8), breast cancer (9), ovarian
cancer (10), colon cancer (11), head and neck carcinoma (12),
hepatoma (13) and melanoma (14). The associations between
CysC levels and survival of malignancies have been explored
in patients with colorectal cancer (15), Non-Hodgkin-B-cell
lymphoma (16) and multiple myeloma (17). All these data
indicated that CysC should be taken into consideration in
cancer monitoring.
However, the potential role of CysC as a prognostic
marker for NPC has not been explored. In the present study,
we retrospectively assessed the relationship between serum
CysC levels and NPC prognosis in a large cohort of NPC
patients receiving long-term follow-up. We also performed
multivariate analyses to determine whether the CysC level is
an independent predictor of the survival of NPC patients.
’ MATERIALS AND METHODS
Patients
This retrospective study was performed on a cohort of
1205 consecutive patients who were newly diagnosed with
stage I to IV NPC at Sun Yat-sen University Cancer Center
(SYSUCC) from June 1, 2006 to December 31, 2010. This
study was reviewed and approved by the Medical Ethics
Committee of SYSUCC.
Patient data were retrieved from the archived patient
medical records and survival data were provided by the
department that performed the follow-up examinations. The
collected data included age, sex, smoking status, TNM stage,
histological type, treatment, time of diagnosis, time of
recurrence and metastasis, and pretreatment CysC level.
We adopted the seventh edition of the AJCC/UICC staging
system for classification of NPC.
Potentially eligible patients had been pathologically
confirmed to suffer from NPC. They also had to have
received comprehensive pretreatment evaluations, including
physical examinations, routine hematological and biochem-
ical examinations, computed tomography or magnetic
resonance imaging of the head and neck, chest X-ray,
abdominal ultrasonography and emission computed tomo-
graphy of the bone.
As the serum CysC level is regulated by renal function, we
excluded those patients with abnormal renal function (GFR
p60 ml/min/1.73 m2 as estimated using the Modification of
Diet in Renal Disease [MDRD] formula) (18). Patients were
also excluded if they had prior malignancies, previous
anticancer therapy, or insufficient biochemical test results
or survival data.
All patients were treated with standard curative radio-
therapy with or without chemotherapy (radiation dose: 60-72
Gy for the nasopharyngeal region, 50-66 Gy for the regional
lymph nodes). Most patients (79.5%) classified as stage III-IV
and a minority of patients (30%) classified as stage II received
a platinum-based chemotherapy regimen.
Assessments
Serum samples were collected from all patients before
treatment. The serum CysC level was measured using the
Hitachi-7080 automated biochemical analyzer (Hitachi, Japan)
according to the manufacturer’s instructions. The assay range
of the serum CysC level is from 0.39 to 6.21 mg/L; the
reference range for healthy persons is from 0.40 to 1.03 mg/L.
The following outcomes were evaluated: overall survival
(OS), progression-free survival (PFS), distant metastasis-free
survival (DMFS), and loco-regional recurrence-free survival
(LRRFS). OS was defined as the time from diagnosis to death
due to any cause. PFS was defined as the time from diagnosis
to tumor progression or death due to any cause. DMFS was
defined as the time from diagnosis to distant metastasis.
LRRFS was defined as the time from diagnosis to loco-
regional recurrence. Data for these events were censored at
the last follow-up if these events did not occur.
Statistical analysis
The qualitative variables were compared using the chi-
square test or the Fisher exact test. A receiver operating
characteristic (ROC) curve was used to determine the
optimal cut-off value of the CysC levels resulting in the
highest sensitivity and specificity. OS, PFS, DMFS and
LRRFS curves were estimated using the Kaplan-Meier
method. The log-rank test was used to compare survival
outcomes. Hazard ratios (HRs) were calculated together with
95% confidence intervals (95% CIs). Multivariate analyses
using a Cox proportional hazards model were performed to
identify independent prognostic factors. Two-sided p-values
less than 0.05 were considered to be statistically significant.
All analyses were conducted using SPSS 18.0.
’ RESULTS
Baseline characteristics
From June 1, 2006, to December 31, 2010, among 1205
potentially eligible patients, we excluded 109 patients for
whom survival and hematological data were insufficient,
4Ćpatients with another type of cancer, 15 patients exhibiting
abnormal kidney function and 14 patients with a history of
renal disease. A total of 1063 patients with newly diagnosed
NPC classified as stage I to IV were included in our study
(Figure 1). The ROC curve analyses revealed that the optimal
CysC cut-off values for OS, PFS, DMFS and LRRFS were
0.945 mg/L, 0.845 mg/L, 0.925 mg/L and 0.765 mg/L,
respectively. The CysC cut-off value of 0.945 mg/L was used
as the uniform point for survival analyses. Thus, all patients
were grouped into either the high CysC (X0.945 mg/L) or
low CysC group (o0.945 mg/L). The distribution of serum
CysC levels is shown in Figure 2.
All patient characteristics are listed in Table 1. The
majority of patients were male (72.0%), never-smokers
(56.8%), classified as stage III-IV (80.7%), and categorized
as WHO type III histological type (95.0%). The high- CysC
group contained more relatively old (X51 years) patients,
more female patients and more patients who received
radiotherapy alone as their primary treatment than the low
CysC group. High and low CysC levels were observed in
13.3% and 86.7% of the entire cohort, respectively.
CysC levels and survival
Until the end of July 2015, among the entire cohort, 218
patients experienced disease progression after primary therapy,
89 patients experienced local disease recurrence, 141 patients
exhibited distant metastasis, and 176 patients had died. At the
time of data cut-off, the median follow-up duration was 68.3
months (95% CI, 67.3 months to 69.4 months). OS was shorter
among the patients in the high CysC group than among the
patients in the low CysC group (HR 1.79, 95% CI 1.22-2.61,
p=0.002; Figure 3A). Additionally, the high CysC group
339
CLINICS 2016;71(6):338-343 Value of cystatin C in nasopharyngeal carcinoma
Yuan J et al.
exhibited significantly shorter PFS (HR 1.67; 95% CI 1.18-2.35,
p=0.003; Figure 3B), DMFS (HR 2.37; 95% CI 1.58-3.55,
po0.001; Figure 3C) and LRRFS than the low CysC group
(HR 2.06; 95% CI 1.19-3.58, p=0.009; Figure 3D).
Univariate and multivariate analyses assessing the
prognostic value of CysC
All recorded characteristics, such as age, sex, smoking
status, histological type, TNM stage, treatment modality and
CysC levels, were examined via univariate analysis (Table 2).
The results revealed that younger age, female gender, never
smoking, early TNM stage, receiving radiotherapy alone, and
a low CysC level were considered as favorable factors for OS.
Moreover, female gender, early TNM stage and receiving
radiotherapy alone, and a low CysC level were considered as
favorable factors for PFS. Furthermore, a low CysC level was
considered as a favorable factor for DMFS. Finally, older age,
receiving radiotherapy alone and a low CysC level were
considered as favorable factors for LRRFS. The CysC level
was associated with all of the examined survival outcomes.
All factors displaying p-values of less than 0.1 based on
univariate analyses were included in the multivariate models
(Table 3). The results demonstrated that a high CysC level
was a significant, independent negative predictor of OS
(HR=1.47, 95% CI=1.00-2.16, p=0.050), PFS (HR=1.65, 95%
CI=1.17-2.34, p=0.004), DMFS (HR=2.37, 95% CI=1.58-3.55,
po0.001), and LRRFS (HR=2.40, 95% CI=1.37-4.21, p=0.002).
Additionally, age was an independent of OS and LRRFS, and
female gender was an independent favorable predictor of OS
and PFS. Furthermore, stage I-II was an independent
favorable factor for OS and receiving radiotherapy alone
was an independent favorable factor for PFS.
’ DISCUSSION
In this retrospective study, which to our knowledge
isĆtheĆfirst to explore the prognostic value of CysC, we
Figure 1 - Flow diagram.
Figure 2 - The distribution of serum cystatin C levels.
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demonstrated that low CysC levels were associated with
longer OS, PFS, DMFS and LRRFS among NPC patients.
AĆlow CysC level was identified as a significant, favorable
predictor or outcomes for patients with NPC, independent of
all other examined clinico-pathological features of NPC.
There is increasing interest in the role of CysC in
malignancies. The study by Kos et al. investigated the
prognostic value of stefin A, stefin B and CysC in 345
patients with colorectal cancer and 125 healthy controls.
They found that high CysC levels were associated with
Table 1 - Baseline clinical characteristics of the 1063 nasopharyngeal carcinoma patients according to their cystatin C levels.
CysC level mean (SD), mg/L CysC level
Characteristics o0.945 mg/L X0.945 mg/L p-value
Age o0.001
o51 years 0.78 (0.49) 484 (52.5) 40 (28.4)
X51 years 0.84 (0.40) 438 (47.5) 101 (71.6)
Gender 0.002
Male 0.74 (0.45) 648 (70.3) 117 (83.0)
Female 0.83 (0.44) 274 (29.7) 24 (17.0)
Smoking status 0.138
Ever 0.84 (0.47) 390 (42.3) 69 (48.9)
Never 0.79 (0.43) 532 (57.7) 72 (51.1)
Histological type 0.208
WHO type I-II 0.76 (0.12) 49 (5.3) 4 (2.8)
WHO type III 0.81 (0.46) 873 (94.7) 137 (97.2)
Stage (7th UICC/AJCC) 0.263
I-II 0.82 (0.60) 183 (19.8) 22 (15.6)
III-IV 0.81 (0.40) 739 (80.2) 119 (84.4)
Treatment 0.038
Radiotherapy 0.83 (0.53) 255 (27.7) 51 (36.2)
Chemo-radiotherapy 0.80 (0.41) 667 (72.3) 90 (63.8)
Abbreviations: CysC: cystatin C; SD: standard deviation; WHO: World Health Organization.
Figure 3 - Kaplan-Meier curves for (a) overall survival, (b) progression-free survival, (c) distant metastasis-free survival, and (d) loco-
regional recurrence-free survival in patients stratified according to the serum cystatin C level.
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shorter survival (15). Mulaomerović et al. reported that CysC
is a potential marker of disease recurrence for patients with
non-Hodgkin B-cell lymphoma (16). Similarly, the study by
Terpos et al. suggested that the serum CysC is an
independent predictor of survival for multiple myeloma
patients (17). Our results are consistent with these findings
suggesting a role of CysC in cancer progression.
The mechanism underlying the association between CysC
levels and NPC patient survival remains unclear. Because
CysC is an inhibitor of cysteine proteases, a low CysC level
facilitates invasiveness of cancer cells in vitro (19,20).
However, in serum, a high CysC level predicts adverse
outcomes. The reasons for the differences in the activities of
CysC in serum and from those in tumors of cancer patients
are complex. First, CysC plays a role in the regulation of
cysteine proteases and other activities involved in tumor
regression (21). As instinct reflexive response to cancer-
induced damage, CysC is secreted into serum by immune
cells. Second, cystatin family members not only act as
cysteine proteases inhibitors but also function in a series of
biological activities such as cell differentiation, proliferation,
migration and immune regulation by stimulating nitric oxide
release from macrophages and by modulating interleukin
and cytokine production in T cells and fibroblasts (22-24).
In the setting of malignancies, CysC may be secreted to
participate in those important cancer-related biological
activities in addition to inhibiting cysteine proteases.
Although the present study is certainly the first to explore
whether the CysC level at the time of diagnosis is associated
with NPC prognosis, several limitations of this study must
be acknowledged. First, we cannot exclude other potential
confounding factors such as physical activity, plasma
Epstein-Barr virus DNA concentrations and family history.
Second, because the prognosis of NPC is favorable, the
follow-up duration for our study cohort is relatively short.
Third, because our study is a single-center study of Chinese
NPC patients, our results may need to be verified in other
ethnic groups.
Despite these shortcomings, our findings demonstrate
forĆthe first time that CysC levels are associated with the
prognosis of NPC patients. A low CysC level is an
independent factor indicating favorable prognosis for NPC
patients. These findings must be validated and explored in
epidemiological, biological and genetic studies.
Table 2 - Univariate analysis of prognostic factors for patients with nasopharyngeal carcinoma.
OS PFS DMFS LRRFS
Factors HR(95%CI) p HR(95%CI) p HR(95%CI) p HR(95%CI) p
Gender
Male vs Female 2.48(1.63-3.79) o0.001 1.67(1.19-2.33) 0.003 1.05(0.73-1.53) 0.779 0.93(0.60-1.47) 0.77
Age (years)
X51 vs o51 1.55(1.14-2.10) 0.005 0.95(0.73-1.24) 0.715 1.19(0.86-1.66) 0.302 0.56(0.36-0.85) 0.007
Smoking status
Ever vs Never 1.58(1.17-2.12) 0.003 1.27(0.98-1.66) 0.074 0.998(0.72-1.39) 0.992 1.01(0.66-1.54) 0.97
Histological type (WHO)
Type III vs type I-II 0.95(0.49-1.86) 0.88 0.99(0.54-1.81) 0.97 3.76(0.93-15.20) 0.063 0.74(0.32-1.68) 0.47
Stage
III-IV vs I-II 2.55(1.52-4.26) o0.001 1.55(1.06-2.26) 0.025 0.91(0.61-1.36) 0.629 1.22(0.70-2.13) 0.48
Treatment
CRT vs RT 1.64(1.14-2.35) 0.008 1.84(1.32-2.58) o0.001 0.95(0.66-1.37) 0.785 1.72(1.01-2.92) 0.044
CysC level (mg/L)
X0.945 vs o0.945 1.79(1.22-2.61) 0.003 1.67(1.18-2.35) 0.004 2.37(1.58-3.55) o0.001 2.06(1.19-3.58) 0.01
CI: confidence interval; OS: overall survival; PFS: progression-free survival; DMFS: distant metastasis-free survival; LRRFS: loco-regional recurrence-free survival.
Table 3 - Multivariate analysis of independent prognostic factors for patients with nasopharyngeal carcinoma.
OS PFS DMFS LRRFS
Factors HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p
Gender
Male vs Female 2.34 (1.53-3.58) o0.001 1.57 (1.12-2.19) 0.009 — — — —
Age (years)
X51 vs o51 1.41 (1.03-1.92) 0.031 — — — — 0.51 (0.33-0.78) 0.002
Smoking status
Ever vs Never 1.13 (0.83-1.56) 0.44 1.07 (0.80-1.42) 0.652 — — — —
Histological type (WHO)
Type III vs type I-II — — — — 3.56 (0.88-14.37) 0.075 — —
Stage
III-IV vs I-II 2.58 (1.54-4.32) o0.001 1.21 (0.81-1.81) 0.355 — — — —
Treatment
CRT vs RT 1.38 (0.94-2.01) 0.1 1.86 (1.33-2.61) o0.001 — — 1.68 (0.99-2.87) 0.057
CysC level (mg/L)
X0.945 vs o0.945 1.47 (1.00-2.16) 0.05 1.65 (1.17-2.34) 0.004 2.37 (1.58-3.55) o0.001 2.40 (1.37-4.21) 0.002
CI: confidence interval; OS: overall survival; PFS: progression-free survival; DMFS: distant metastasis-free survival; LRRFS: loco-regional recurrence-free
survival.
‘‘—’’ indicates that the factor was not included in the multivariate analysis because its p-value based on univariate analysis was greater than 0.1.
342
Value of cystatin C in nasopharyngeal carcinoma
Yuan J et al.
CLINICS 2016;71(6):338-343
’ AUTHOR CONTRIBUTIONS
Yuan J conceived and designed the study, analyzed and interpreted the
data, wrote the manuscript and conducted literature searches. Xu M
conceived and designed the study and critically revised the manuscript.
Li J and Li N collected and analyzed all data related to this study.
Chen LZ and Feng QS reviewed the records. Zeng YX is the supervisor of
the study who approved the ﬁnal version of the manuscript.
’ REFERENCES
1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):
2041-54, http://dx.doi.org/10.1016/S0140-6736(05)66698-6.
2. McDermott AL, Dutt SN, Watkinson JC. The aetiology of
nasopharyngealĆcarcinoma. Clin Otolaryngol Allied Sci. 2001;26(2):82-92,
http://dx.doi.org/10.1046/j.1365-2273.2001.00449.x.
3. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M. Cancer
incidence in five continents, vol. IX. IARC Scientific Publication No 160.
2007.
4. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary
results of a randomized study on therapeutic gain by concurrent
chemotherapy for regionally-advanced nasopharyngeal carcinoma:
NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study
Group. J Clin Oncol. 2005;23(28):6966-75, http://dx.doi.org/10.1200/
JCO.2004.00.7542.
5. Keppler D. Towards novel anti-cancer strategies based on cystatin func-
tion. Cancer Lett. 2006;235(2):159-76, http://dx.doi.org/10.1016/j.canlet.
2005.04.001.
6. Abrahamson M, Grubb A, Olafsson I, Lundwall A. Molecular cloning and
sequence analysis of cDNA coding for the precursor of the human
cysteine proteinase inhibitor cystatin C. FEBS Lett. 1987;216(2):229-33,
http://dx.doi.org/10.1016/0014-5793(87)80695-6.
7. Akerblom A, Helmersson-Karlqvist J, Flodin M, Larsson A.
ComparisonĆbetween Cystatin C- and Creatinine-Estimated Glomerular
Filtration Rate in Cardiology Patients. Cardiorenal Med. 2015;5(4):289-96,
http://dx.doi.org/10.1159/000437273.
8. Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y, et al. Detection of cathepsin
B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase
plasminogen activator receptor in the sera of lung cancer patients. Oncol
Lett. 2011;2(4):693-9, http://dx.doi.org/10.3892/ol.2011.302.
9. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D’Amico C,
Leto G. Serum interleukin-6 in patients with metastatic bone
disease: correlation with cystatin C. Med Oncol. 2009;26(1):10-5,
http://dx.doi.org/10.1007/s12032-008-9070-2.
10. Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A,
et al. The role of cathepsin B and cystatin C in the mechanisms
ofĆinvasion by ovarian cancer. Gynecol Oncol. 2004;92(3):881-6,
http://dx.doi.org/10.1016/j.ygyno.2003.11.017.
11. Saleh Y, Sebzda T, Warwas M, Kopec W, Ziolkowska J, Siewinski M.
Expression of cystatin C in clinical human colorectal cancer tissues. J Exp
Ther Oncol. 2005;5(1):49-53.
12. Strojan P, Svetic B, Smid L, Kos J. Serum cystatin C in patients
with head and neck carcinoma. Clin Chim Acta. 2004;344(1-2):155-61,
http://dx.doi.org/10.1016/j.cccn.2004.02.011.
13. He H, Lu RX, Xu J, Liang LB, Zhang MF, An ZM, et al. [Preliminary study
on the expression of cystatin C in primary liver cancer]. Sichuan Da Xue
Xue Bao Yi Xue Ban. 2013;44(6):920-3.
14. Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N,
et al. Cathepsins B, H, and L and their inhibitors stefin A and
cystatin C in sera of melanoma patients. Clin Cancer Res. 1997;3(10):
1815-22.
15. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N.
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera
from patients with colorectal cancer: relation to prognosis. Clin Cancer
Res. 2000;6(2):505-11.
16. Mulaomerovic A, Halilbasic A, Cickusic E, Zavasnik-Bergant T, Begic L,
Kos J. Cystatin C as a potential marker for relapse in patients withĆ
non-Hodgkin B-cell lymphoma. Cancer Lett. 2007;248(2):192-7,
http://dx.doi.org/10.1016/j.canlet.2006.07.004.
17. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A,
et al. Cystatin-C is an independent prognostic factor for survival
in multiple myeloma and is reduced by bortezomib administration.
Haematologica. 2009;94(3):372-9, http://dx.doi.org/10.3324/haematol.
2008.000638.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from
serumĆcreatinine: a new prediction equation. Modification of Diet
inĆRenalĆDisease Study Group. Ann Intern Med. 1999;130(6):461-70,
http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00002.
19. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL,
et al. Cystatin C is downregulated in prostate cancer and modulates
invasion of prostate cancer cells via MAPK/Erk and androgen receptor
pathways. PLoS One. 2009;4(11):e7953, http://dx.doi.org/10.1371/jour-
nal.pone.0007953.
20. Wallin H, Abrahamson M, Ekstrom U. Cystatin C properties
crucial for uptake and inhibition of intracellular target enzymes.
J Biol Chem. 2013;288(23):17019-29, http://dx.doi.org/10.1074/jbc.
M113.453449.
21. Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth
factor beta signaling in normal and cancer cells. Mol Cancer Res. 2004;
2(3):183-95.
22. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B.
Chicken cystatin stimulates nitric oxide release from interferon-gamma-
activated mouse peritoneal macrophages via cytokine synthesis.
Eur J Biochem. 1999;266(3):1111-7, http://dx.doi.org/10.1046/j.1432-
1327.1999.00964.x.
23. Das L, Datta N, Bandyopadhyay S, Das PK. Successful therapy of lethal
murine visceral leishmaniasis with cystatin involves up-regulation of
nitric oxide and a favorable T cell response. J Immunol. 2001;166(6):4020-8,
http://dx.doi.org/10.4049/jimmunol.166.6.4020.
24. Verdot L, Lalmanach G, Vercruysse V, Hartmann S, Lucius R, Hoebeke J,
et al. Cystatins up-regulate nitric oxide release from interferon-gamma-
activated mouse peritoneal macrophages. J Biol Chem. 1996;271(45):
28077-81, http://dx.doi.org/10.1074/jbc.271.45.28077.
343
CLINICS 2016;71(6):338-343 Value of cystatin C in nasopharyngeal carcinoma
Yuan J et al.
